Celltrion Sees Multiple Biosimilar Opportunities From Trump’s Pricing EO

Direct Sales At Lower Prices?

 
• By Jung Won Shin
  
big opportunity
Trump’s Executive Orders May Positively Impact Biosimilar Industry (Shutterstock)

More from South Korea

More from Drug Pricing